3-propoxy-thiophene-2-carboxylic acid | 821005-21-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 3-propoxy-thiophene-2-carboxylic acid
• 英文别名: 3-Propoxythiophene-2-carboxylic acid
• CAS: 821005-21-4
• 化学式: C₈H₁₀O₃S
• 分子量: 186.232
• InChiKey: NOCGTFKCRFTUQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  74.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  、 3-propoxy-thiophene-2-carboxylic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以54%的产率得到[4-[(3R)-4-[(1S)-1-[4-[2-(1,3-benzodioxol-5-yl)ethyl]phenyl]ethyl]-3-methylpiperazin-1-yl]piperidin-1-yl]-(3-propoxythiophen-2-yl)methanone
  参考文献：
  名称：

  MCH antagonists for the treatment of obesity

  摘要：

  本发明公开了使用黑素浓缩激素（MCH）拮抗剂治疗肥胖、代谢紊乱、食欲紊乱（如过度进食）和糖尿病的方法，以及作为黑素浓缩激素（MCH）拮抗剂的新化合物。在其他方面，本发明涉及包含这种MCH拮抗剂的药物组合物，以及制备这种化合物的方法。本发明的化合物通常具有以下结构： 其中取代基如本文所定义。

  公开号：

  US20050004121A1

文献信息

• N-substituted indole derivatives as PGE2 receptor modulators
  申请人：Idorsia Pharmaceuticals Ltd

  公开号：US11241431B2

  公开（公告）日：2022-02-08

  The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

  本发明涉及式 (I) 的衍生物 其中 (R1)n、R2、R3、R4a、R4b、R5a、R5b 和 Ar1 如说明书所述，涉及它们的制备、它们的药学上可接受的盐，以及它们作为药物的用途、含有一种或多种式 (I) 化合物的药物组合物，特别是它们作为前列腺素 2 受体 EP2 和/或 EP4 的调节剂的用途。
• MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY
  申请人：SCHERING CORPORATION

  公开号：EP1644366A1

  公开（公告）日：2006-04-12
• N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20200289507A1

  公开（公告）日：2020-09-17

  The present invention relates to derivatives of formula (I) wherein (R 1 ) n , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b and Ar 1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
• US7345042B2
  申请人：——

  公开号：US7345042B2

  公开（公告）日：2008-03-18
• [EN] MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY<br/>[FR] ANTAGONISTES DE MCH POUR LE TRAITEMENT DE L'OBESITE
  申请人：SCHERING CORP

  公开号：WO2005005419A1

  公开（公告）日：2005-01-20

  The present invention discloses methods of using antagonists for melanin-concentrating hormone (MCH), to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes, as well as novel compounds which are antagonists for melanin-concentrating hormone (MCH). In other aspects, the invention is directed to pharmaceutical compositions comprising such MCH antagonists as well as methods for preparing such compounds. Compounds of the invention generally have the structure of formula (I) where the substituents are as defined herein.